Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|January 30, 2004
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasisU R Kleeberg, S Suciu, E B Bröcker, et al.
Journal of the National Cancer Institute|April 21, 1993
Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study GroupH Döhner, A D Ho, J Thaler, et al.
European Journal of Cancer & Clinical Oncology|February 1, 1989
Relation between estrogen receptor concentration and clinical and histological factors: their relative prognostic importance after radical mastectomy for primary breast cancerG Andry, S Suciu, D Pratola, et al.
Cancer Investigation|January 1, 1996
Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia GroupH H Gerhartz, H H Zwierzina, J Walther, et al.
Seminars in Oncology|July 6, 2000
Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of CancerA D Ho, S Suciu, P Stryckmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative GroupA D Ho, S Suciu, P Stryckmans, et al.
The New England Journal of Medicine|August 27, 1998
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative GroupH Cavé, J van der Werff ten Bosch, S Suciu, et al.
Bone Marrow Transplantation|August 1, 1997
Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trialR Zittoun, S Suciu, M Watson, et al.
Annals of Hematology|March 1, 1996
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative GroupT De Witte, S Suciu, D Selleslag, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2010
Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952M G Bouwhuis, S Suciu, W Kruit, et al.
Pageof 12